Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.7554
Nov 19 • 11:19 AM ET Dollar change-0.0247 Percentage change(-3.17%)
Index
RUT
Market Cap
91.22M
Enterprise Value
-106.79M
Income
-122.91M
Sales
0.22M
Book/sh
2.58
Cash/sh
1.67
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
166
IPO
Nov 10, 2005
P/E
-
Forward P/E
-
PEG
-
P/S
414.62
P/B
0.29
P/C
0.45
P/FCF
-
EV/EBITDA
-
EV/Sales
-485.42
Quick Ratio
5.18
Current Ratio
5.18
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-1.25
EPS next Y
-1.02
EPS next Q
-0.27
EPS this Y
29.94%
EPS next Y
-3.17%
EPS next 5Y
12.64%
EPS past 3/5Y
-39.72% -22.26%
Sales past 3/5Y
-56.57% -38.04%
EPS Y/Y TTM
14.45%
Sales Y/Y TTM
-79.53%
EPS Q/Q
23.12%
Sales Q/Q
-90.43%
Insider Own
16.74%
Insider Trans
-1.52%
Inst Own
72.56%
Inst Trans
-1.64%
ROA
-37.28%
ROE
-45.86%
ROIC
-41.36%
Gross Margin
-1932.27%
Oper. Margin
-55315.00%
Profit Margin
-55866.82%
SMA20
-22.80%
SMA50
-60.97%
SMA200
-77.57%
Trades
Shs Outstand
114.16M
Shs Float
100.55M
52W High
6.16 -87.74%
52W Low
0.78 -3.09%
Volatility
12.62% 16.18%
ATR (14)
0.15
RSI (14)
25.28
Beta
2.09
Rel Volume
0.75
Avg Volume
2.67M
Volume
635,447
Perf Week
-10.33%
Perf Month
-67.16%
Perf Quarter
-77.11%
Perf Half Y
-80.48%
Perf YTD
-72.53%
Perf Year
-67.16%
Perf 3Y
-70.97%
Perf 5Y
-84.59%
Perf 10Y
-86.86%
Prev Close
0.78
Price
0.76
Change %
-3.17%
Consensus
Strong Buy
Avg. Price Target
$9.25
Implied Upside
+1,124.5%
Analysts12incl. previous ratings
Rating Distribution10 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 26, 2026Downgrade
RY logoRRBC Capital Mkts
Outperform → Sector Perform$4+429.5%
Sep 18, 2026Initiated
WWilliam Blair
Outperform
Aug 19, 2026Initiated
BMO logoBBMO Capital Markets
Outperform$11+1,356.2%
Feb 19, 2026Initiated
PPiper Sandler
Overweight$16+2,018.1%
Nov 24, 2025Resumed
TFC logoTTruist
Buy$12+1,488.6%
Oct 10, 2025Initiated
BBTIG Research
Buy$14+1,753.3%
Mar 13, 2025Initiated
HH.C. Wainwright
Buy$10+1,223.8%
Mar 07, 2025Initiated
BNS logoBScotiabank
Sector Outperform$15+1,885.7%
Nov 25, 2024Downgrade
BAC logoBBofA Securities
Buy → Neutral$24 → $5+561.9%
Oct 24, 2024Initiated
UBS logoUUBS
Buy$20+2,547.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Williamson Robert F IIIDirectorNov 18 '26Buy0.8015,00012,00068,473Nov 19 08:30 AM
Williamson Robert F IIIDirectorNov 17 '26Buy0.8425,00020,95053,473Nov 18 08:20 AM
Morich FrankDirectorNov 16 '26Buy0.9415,00014,04630,000Nov 17 08:30 AM
Morich FrankDirectorNov 12 '26Buy1.0015,00014,95615,000Nov 16 08:30 AM
Williamson Robert F IIIDirectorNov 12 '26Buy0.8418,60915,63228,473Nov 16 08:30 AM
Williamson Robert F IIIDirectorNov 12 '26Buy0.846,2895,274115,271Nov 16 08:30 AM
Woods Lori ADirectorNov 12 '26Buy0.8423,75020,04028,557Nov 16 08:30 AM
Puhlmann MarkusChief Medical OfficerNov 12 '26Buy0.8435,00029,564178,542Nov 13 08:30 AM
Puhlmann MarkusChief Medical OfficerNov 11 '26Buy0.836,0004,980143,542Nov 13 08:30 AM
Spoor Johan M.Chief Executive OfficerNov 11 '26Buy0.8147,00037,943106,383Nov 12 08:30 AM
Lantheus Alpha Therapy, LLC10% OwnerSep 04 '26Sale3.15167,149526,05111,273,364Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC10% OwnerSep 03 '26Sale3.1180,783250,89611,440,513Sep 08 04:51 PM
Lantheus Alpha Therapy, LLC10% OwnerSep 02 '26Sale3.1142,129131,21911,521,296Sep 04 05:00 PM
Lantheus Alpha Therapy, LLC10% OwnerAug 31 '26Sale3.1478,145245,61011,599,194Sep 04 04:58 PM
Lantheus Alpha Therapy, LLC10% OwnerSep 01 '26Sale3.1235,769111,57411,563,425Sep 04 04:58 PM
Lantheus Holdings, Inc.10% OwnerSep 01 '26Sale3.1235,769111,57411,563,425Sep 03 04:54 PM
Lantheus Holdings, Inc.10% OwnerAug 31 '26Sale3.1478,145245,61011,599,194Sep 02 04:36 PM
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded by Michael K. Schultz in 1983 and is headquartered in Seattle, WA.
CEO & DirectorMr. Johan M. Spoor
CFO & Principal Financial OfficerMr. Joel David Sendek
M.D.Dr. Markus Puhlmann M.B.A.
Co-Founder & Senior Scientific AdvisorDr. Michael K. Schultz Ph.D.
Executive Vice President of OperationsMr. Shane Cobb